Syndax Drops Lung Disease Drug
Syndax Pharmaceuticals is ending the development of a lung disease treatment after a mid-stage trial failed to meet its primary goal. The company confirmed that shares fell about 17 percent in extended trading following the announcement.
Xurve View
Insights:
Xurve View
Syndax Pharmaceuticals dropped its lung-disease drug after a mid-stage trial failed, sending shares tumbling 17% in extended trading. The 26-week study across 62 sites missed its primary endpoint of reducing lung function decline. Investors must weigh the pipeline setback against ongoing revenue from the drug's approved indications.
